{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T08:48:46Z","timestamp":1782377326824,"version":"3.54.5"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajconline.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.amjcard.2026.04.064","type":"journal-article","created":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T22:14:23Z","timestamp":1777846463000},"page":"176-181","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Comparative Risk of Adverse Cardiovascular Outcomes With Zanubrutinib Versus Ibrutinib in B-Cell Malignancies: A Large Real-World Propensity-Matched Analysis"],"prefix":"10.1016","volume":"271","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-1727-6411","authenticated-orcid":false,"given":"Usama","family":"Qamar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeeshan","family":"Imtiaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Hassan","family":"Jan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddharth","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satyam","family":"Krishan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manu","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sami","family":"Ibrahimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Bilal","family":"Munir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taha-Al","family":"Juhaishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zain Ul Abideen","family":"Asad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2026.04.064_bib0001","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/S0140-6736(24)00595-6","article-title":"Chronic lymphocytic leukemia","volume":"404","author":"Jain","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2026.04.064_bib0002","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S1470-2045(24)00141-4","article-title":"Long-term survival for lymphoid neoplasms and national health expenditure (EUROCARE-6): a retrospective, population-based study","volume":"25","author":"Sant","year":"2024","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.amjcard.2026.04.064_bib0003","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25063234","article-title":"Targeting BTK in B cell malignancies: from mode of action to resistance mechanisms","volume":"25","author":"Mouhssine","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.amjcard.2026.04.064_bib0004","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1007\/s40265-018-1003-6","article-title":"Targeting Bruton\u2019s tyrosine kinase across B-cell malignancies","volume":"78","author":"Cunha-Bang","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.amjcard.2026.04.064_bib0005","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia","volume":"371","author":"Byrd","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2026.04.064_bib0006","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1001\/jama.2023.1946","article-title":"Diagnosis and treatment of chronic lymphocytic leukemia","volume":"329","author":"Shadman","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2026.04.064_bib0007","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1182\/blood.2019001160","article-title":"Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL","volume":"134","author":"Tam","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.amjcard.2026.04.064_bib0008","unstructured":"DailyMed, Brukinsa (zanubrutinib) drug information, (n.d.). https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=3e08fe23-d70e-424c-bc51-1222e320f902. Accessed on December 20, 2025"},{"key":"10.1016\/j.amjcard.2026.04.064_bib0009","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa2211582","article-title":"Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia","volume":"388","author":"Brown","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2026.04.064_bib0010","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1182\/blood.2020006844","article-title":"A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstr\u00f6m macroglobulinemia: the ASPEN study","volume":"136","author":"Tam","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.amjcard.2026.04.064_bib0011","unstructured":"TriNetX, Real-world data for the life sciences and healthcare, (2025). https:\/\/trinetx.com\/. Accessed on December 2, 2025"},{"key":"10.1016\/j.amjcard.2026.04.064_bib0012","unstructured":"EQUATOR Network, RECORD-PE reporting guidelines, (n.d.). https:\/\/www.equator-network.org\/reporting-guidelines\/record-pe\/. Accessed on December 27, 2025"},{"key":"10.1016\/j.amjcard.2026.04.064_bib0013","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies","volume":"46","author":"Austin","year":"2011","journal-title":"Multivariate Behav Res"},{"key":"10.1016\/j.amjcard.2026.04.064_bib0014","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life-tables","volume":"34","author":"Cox","year":"1972","journal-title":"J R Stat Soc B"},{"key":"10.1016\/j.amjcard.2026.04.064_bib0015","series-title":"Modelling survival data in medical research","author":"Collett","year":"2015"},{"key":"10.1016\/j.amjcard.2026.04.064_bib0016","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyaf237","article-title":"Considerations for the practical management of cardiovascular risk with Bruton\u2019s tyrosine kinase inhibitors for patients with chronic lymphocytic leukemia","volume":"30","author":"Lenihan","year":"2025","journal-title":"Oncologist"},{"key":"10.1016\/j.amjcard.2026.04.064_bib0017","first-page":"1","article-title":"Comparative safety of different first-line treatments for chronic lymphocytic leukemia\/small lymphocytic lymphoma: a systematic review and network meta-analysis","volume":"104","author":"Liu","year":"2025","journal-title":"Ann Hematol"},{"key":"10.1016\/j.amjcard.2026.04.064_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2025.101268","article-title":"BTKi-induced cardiovascular toxicity in CLL: risk mitigation and management strategies","volume":"70","author":"Kozarac","year":"2025","journal-title":"Blood Rev"},{"key":"10.1016\/j.amjcard.2026.04.064_bib0019","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1016\/S2352-3026(22)00320-9","article-title":"Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study","volume":"10","author":"Shadman","year":"2023","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.amjcard.2026.04.064_bib0020","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.14542.1","article-title":"Cardio-oncology: management of cardiovascular toxicity","author":"Markman","year":"2019","journal-title":"F1000Research"},{"key":"10.1016\/j.amjcard.2026.04.064_bib0021","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.3390\/cancers15113055","article-title":"Cardiovascular complications of pan-cancer therapies: the need for cardio-oncology","volume":"15","author":"Chen","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.amjcard.2026.04.064_bib0022","doi-asserted-by":"crossref","first-page":"5099","DOI":"10.1200\/JCO.22.02830","article-title":"Zanubrutinib versus ibrutinib in symptomatic Waldenstr\u00f6m macroglobulinemia: final analysis from the randomized phase III ASPEN study","volume":"41","author":"Dimopoulos","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.amjcard.2026.04.064_bib0023","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1200\/JCO.21.01210","article-title":"Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial","volume":"39","author":"Byrd","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.amjcard.2026.04.064_bib0024","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMsb1609216","article-title":"Real-world evidence \u2014 What is it and what can it tell us?","volume":"375","author":"Sherman","year":"2016","journal-title":"N Engl J Med"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914926003188?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914926003188?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T08:18:01Z","timestamp":1782375481000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914926003188"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":24,"alternative-id":["S0002914926003188"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2026.04.064","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative Risk of Adverse Cardiovascular Outcomes With Zanubrutinib Versus Ibrutinib in B-Cell Malignancies: A Large Real-World Propensity-Matched Analysis","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2026.04.064","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}